There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...